



Activation studies of the β -carbonic anhydrases from *Malassezia restricta* with amines and amino acids

Andrea Angeli, Sonia Del Prete, Cynthia Ghobril, Julien Hitce, Cécile Clavaud, Xavier Marrat, William A. Donald, Clemente Capasso & Claudiu T. Supuran

To cite this article: Andrea Angeli, Sonia Del Prete, Cynthia Ghobril, Julien Hitce, Cécile Clavaud, Xavier Marrat, William A. Donald, Clemente Capasso & Claudiu T. Supuran (2020) Activation studies of the β -carbonic anhydrases from *Malassezia restricta* with amines and amino acids, Journal of Enzyme Inhibition and Medicinal Chemistry, 35:1, 824-830, DOI: [10.1080/14756366.2020.1743284](https://doi.org/10.1080/14756366.2020.1743284)

To link to this article: <https://doi.org/10.1080/14756366.2020.1743284>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 27 Mar 2020.



Submit your article to this journal [↗](#)



Article views: 997



View related articles [↗](#)






View Crossmark data [↗](#)

RESEARCH PAPER



Activation studies of the β -carbonic anhydrases from *Malassezia restricta* with amines and amino acids

Andrea Angeli^a , Sonia Del Prete^b, Cynthia Ghobril^c, Julien Hitce^c, Cécile Clavaud^c, Xavier Marrat^c, William A. Donald^d, Clemente Capasso^b  and Claudiu T. Supuran^{a,d} 

^aDipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Sesto Fiorentino (Florence), Italy; ^bDepartment of Biology, Agriculture and Food Sciences, Institute of Biosciences and Bioresources, CNR, Napoli, Italy; ^cL'Oréal Research and Innovation, Aulnay-sous-Bois, France; ^dSchool of Chemistry, University of New South Wales, Sydney, New South Wales, Australia

ABSTRACT

The β -carbonic anhydrase (CA, EC 4.2.1.1) from the genome of the opportunistic pathogen *Malassezia restricta* (MreCA), which was recently cloned and characterised, herein has been investigated for enzymatic activation by a panel of amines and amino acids. Of the 24 compounds tested in this study, the most effective MreCA activators were L-adrenaline (K_A of 15 nM), 2-aminoethyl-piperazine/morpholine (K_{AS} of 0.25–0.33 μ M), histamine, L-4-amino-phenylalanine, D-Phe, L-/D-DOPA, and L-/D-Trp (K_{AS} of 0.32 – 0.90 μ M). The least effective activators were L-/D-Tyr, L-Asp, L-/D-Glu, and L-His, with activation constants ranging between 4.04 and 12.8 μ M. As MreCA is involved in dandruff and seborrhoeic dermatitis, these results are of interest to identify modulators of the activity of enzymes involved in the metabolic processes of such fungi.

ARTICLE HISTORY


Received 16 February 2020
Revised 5 March 2020
Accepted 10 March 2020

KEYWORDS

Carbonic anhydrase;
activator; β -class enzyme;
pathogenic fungi; amine;
amino acid

1. Introduction

Carbonic anhydrases (CAs; EC 4.2.1.1) are present in most organisms investigated to date^{1–5}, with eight genetically distinct classes of such enzymes, the α -, β -, γ -, δ -, ζ -, η -, θ -, and ι -CA classes being encoded in the genome of various organisms^{6–8}. They all catalyse the simple but fundamental interconversion reaction between carbon dioxide and bicarbonate, with the concomitant generation of hydronium ions:







α -CAs are Zn^{2+} metalloproteins expressed in vertebrates, fungi, protozoa, algae, plants and prokaryotes^{4–9}. The β -CAs are also Zn^{2+} enzymes and they are present in bacteria, fungi, protozoa and chloroplasts of mono-/dicotyledon plants^{4,5}. γ -CAs are probably Zn^{2+} or Fe^{2+} enzymes, although it has been shown they are also active with Co^{2+} within their active site, and are present in archaea, bacteria and plants^{3,4}. Limited information is known about δ -CAs, which are zinc- or cobalt-containing enzymes present in marine diatoms^{7,10}. The ζ -CAs are active with Cd^{2+} or Zn^{2+} at their active site, and were also identified in marine diatoms¹¹. η -CA are Zn^{2+} metalloproteins identified in *Plasmodium* spp. and other protozoans¹². The recently identified θ - and ι -CAs are also present in marine diatoms^{11,13}, and the latter class is also expressed in bacteria and are likely Mn(II) metalloenzymes, as recently reported¹³.

Various classes of inhibitors of these enzymes, mainly targeting mammalian CAs, are in clinical use as diuretics, antiglaucoma, anti-epileptic or antiobesity agents for decades, whereas their use as anticancer agents started to be contemplated only in the last

decade^{1,2,6,14–18}. There has also been recent interest in inhibiting CAs in various pathogenic bacteria to develop anti-infective applications^{6–8}. These diverse applications are due to the fact that at least 15 different α -CA isoforms are present in humans, being involved in critical physiological and pathological processes^{14–18}.

Activation studies of various classes of CAs, among which the β -, γ -, δ -, ζ -, and η -CA classes were explored only recently, and only with two classes of modulators of activity, the amines and the amino acids^{3,19}. The catalytic mechanism of these enzymes is also well understood and explains also their activation mechanism³. A metal hydroxide species present in the active site of these enzymes acts as a strong nucleophile (at physiologic pH) for converting the CO_2 to bicarbonate, which is thereafter coordinated to the catalytic metal ion. This adduct is not very stable and its reaction with an incoming water molecule leads to the liberation of bicarbonate in solution and generation of an acidic form of the enzyme incorporating an $\text{M}^{2+}(\text{OH}_2)$ species at the metal centre, which is catalytically ineffective for the hydration of CO_2 ^{1–3}. To generate the nucleophilic $\text{M}^{2+}(\text{OH}^-)$ species, a proton transfer reaction occurs, which determines the rate for the catalytic cycle in many of these types of very efficient enzymes. For many α -CAs this step is assisted by a proton shuttle residue, which is His64 in most mammalian isoforms²⁰. This is one of the few residues in α -CAs possessing a flexible conformation, with an inward (*in* conformation) and outward (*out*) conformation. For this reason, the imidazole moiety of this histidine, with a $\text{p}K_a$ of 6.0–7.5 (depending on the isoform³) is an appropriate proton shuttling residue which transfers the proton from the metal coordinated water to the reaction medium, in a crucially important and rate-

CONTACT Clemente Capasso  clemente.capasso@ibbr.cnr.it  Department of Biology, Agriculture and Food Sciences, CNR, Institute of Biosciences and Bioresources, CNR, Via Pietro Castellino 111, 80131, Napoli, Italy; Claudiu T. Supuran  claudiu.supuran@unifi.it  Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Via U. Schiff 6, 50019, Sesto Fiorentino, Florence, Italy

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.







Figure 1. Amino acids and amines 1–24 investigated as CAAs in the present article.

determining step of the catalytic cycle^{1–3}. The process can also be assisted by endogenous molecules, which bind within the enzyme active site, as proven by X-ray crystallography and other techniques, which have been termed CA activators (CAAs)¹⁹. Such activators facilitate the proton transfer reactions between the metal ion centre and the external medium by an alternative pathway to the proton shuttle residue. The two reactions of the CA catalytic cycle are shown by Equations (1) and (2), with the deprotonation of zinc-bound water being the rate-determining step (Equation (2))^{19,21}. This leads to the generation of the active form of the enzyme^{3,19,22}:



In the presence of an activator molecule “A”, Equation (2) becomes Equation (3); that is, in the enzyme-activator complex the proton transfer reaction is no longer intermolecular but intramolecular, and thus favoured^{3,19}:



Enzyme-activator complexes

CAAs were recently demonstrated to have potential pharmacologic applications²³, as the activation of mammalian enzymes was

shown to enhance cognition and memory in experimental animals^{23a,b}, whereas its inhibition had the opposite effect¹⁴.

The activation of CAs from pathogenic bacteria may also be relevant for understanding the factors governing virulence and colonisation of the host, because pH in the tissues surrounding the pathogens likely plays a key role in such processes^{3,5} and many compounds that are CAAs (biogenic amines and amino acid derivatives) are abundant in such tissues. Considering such evidence, in this study we report an activation study with amines and amino acids (compounds 1–24, Figure 1) of the β -CA recently reported and characterised biochemically from the dandruff producing organism *Malassezia restricta*²⁴.

2. Materials and methods

2.1. Enzymes production and purification

The protocol described in the previous works²⁴ has been used to obtain purified recombinant MreCA.

2.2. Ca activity/activation measurements

An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay the catalytic activity of various CA isozymes for CO₂ hydration reaction²⁵. Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.5, for

α -CAs)^{26–29} or TRIS (pH 8.3, for β -CAs)^{30–33} as buffers, 0.1 M NaClO₄ (for maintaining constant ionic strength), following the CA-catalyzed CO₂ hydration reaction for a period of 10 s at 25 °C. The CO₂ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each activator at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of activators (at 0.1 mM) were prepared in distilled-deionized water and dilutions up to 1 nM were made thereafter with the assay buffer. Enzyme and activator solutions were pre-incubated together for 15 min prior to assay, in order to allow for the formation of the enzyme–activator complexes. The activation constant (K_A), defined similarly with the inhibition constant K_i , can be obtained by considering the classical Michaelis–Menten equation (Equation (4)), which has been fitted by non-linear least squares by using PRISM 3:

$$v = v_{\max} / \{1 + (K_M/[S])(1 + [A]_f/K_A)\} \quad (4)$$

where $[A]_f$ is the free concentration of activator.

Working at substrate concentrations considerably lower than K_M ($[S] \ll K_M$), and considering that $[A]_f$ can be represented in the form of the total concentration of the enzyme ($[E]_t$) and activator ($[A]_t$), the obtained competitive steady-state equation for determining the activation constant is given by Equation (5):

$$v = v_0 \cdot K_A / \left\{ K_A + \left([A]_t - 0.5 \left\{ ([A]_t + [E]_t + K_A) - ([A]_t + [E]_t + K_A)^2 - 4[A]_t \cdot [E]_t \right\}^{1/2} \right) \right\} \quad (5)$$

where v_0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator^{3,30–35}. This type of approach to measuring enzyme–ligand interactions is in excellent agreement with recent results from native mass spectrometry measurements³⁶.

2.3. Reagents

Amines and amino acid derivatives **1–24** were obtained in the highest purity that was available commercially from Sigma-Aldrich (Milan, Italy).

3. Results and discussion

We measured the kinetics constants (k_{cat} and K_M) of the recently described β -CA from *M. restricta*, MreCA, for comparison to those of the thoroughly studied human (h) CA isoforms hCA I and II, belonging to the α -CA class (Table 1). The experiments were also performed in the presence of 10 μ M L-Trp as activator.

The data in Table 1 indicates that the presence of L-Trp does not change the K_M both for the two enzymes belonging to the α -class (hCA I/II) as well as for MreCA, a situation also observed for all CA classes for which CA activators have been investigated so far^{3,29–33}. In fact, as proven by kinetic and crystallographic data^{3,20}, the activator binds in a diverse binding region within the active site of the substrate binding site. Thus, the activator does not influence K_M but has an effect only on the k_{cat} . Indeed, a 10 μ M concentration of L-Trp leads to a 9-fold enhancement of the kinetic constant of MreCA compared to the same parameter in the absence of the activator (Table 1). For hCA I and II, the enhancement of the kinetic constant in the presence of L-Trp was

Table 1. Activation of hCA I, II and MreCA with L-Trp, at 25 °C, for the CO₂ hydration reaction²⁵.

Enzyme	k_{cat}^a (s ⁻¹)	K_M^a (mM)	$(k_{\text{cat}})_{\text{L-Trp}}^b$ (s ⁻¹)	K_A^c (μ M) L-Trp
hCA I ^d	2.0×105	4.0	3.4×105	44.0
hCA II ^d	1.4×106	9.3	4.9×106	27.0
MreCA ^e	1.06×106	9.9	9.6×106	0.32

^aObserved catalytic rate without activator. K_M values in the presence and the absence of activators were the same for the various CAs (data not shown).

^bObserved catalytic rate in the presence of 10 μ M activator.

^cThe activation constant (K_A) for each enzyme was obtained by fitting the observed catalytic enhancements as a function of the activator concentration²⁵. Mean from at least three determinations by a stopped-flow, CO₂ hydrase method²⁵. Standard errors were in the range of 5–10% of the reported values (data not shown).

^dHuman recombinant isozymes, from work by Capasso and Supuran³².

^eFungal recombinant enzyme, this work.

Table 2. Activation constants of hCA I, hCA II and MreCA with amino acids and amines **1–24** by a stopped-flow CO₂ hydrase assay²⁵.

No.	Compound	K_A (μ M) ^a		
		hCA I ^b	hCA II ^c	MreCA ^c
1	L-His	0.03	10.9	12.8
2	D-His	0.09	43	1.84
3	L-Phe	0.07	0.013	2.69
4	D-Phe	86	0.035	0.76
5	L-DOPA	3.1	11.4	0.87
6	D-DOPA	4.9	7.8	0.70
7	L-Trp	44	27	0.32
8	D-Trp	41	12	0.89
9	L-Tyr	0.02	0.011	4.15
10	D-Tyr	0.04	0.013	7.83
11	4-H ₂ N-L-Phe	0.24	0.15	0.61
12	Histamine	2.1	125	0.90
13	Dopamine	13.5	9.2	2.71
14	Serotonin	45	50	0.82
15	2-Pyridyl-methylamine	26	34	0.34
16	2-(2-Aminoethyl)pyridine	13	15	2.13
17	1-(2-Aminoethyl)-piperazine	7.4	2.3	0.25
18	4-(2-Aminoethyl)-morpholine	0.14	0.19	0.33
19	L-Adrenaline	0.09	96.0	0.015
20	L-Asn	11.3	>100	0.93
21	L-Asp	5.20	>100	4.04
22	L-Glu	6.43	>100	5.26
23	D-Glu	10.7	>100	4.70
24	L-Gln	>100	>50	0.90

^aMean from three determinations by a stopped-flow, CO₂ hydrase method²⁵. Standard errors were in the range of 5–10% of the reported values (data not shown).

^bHuman recombinant isozymes, from the work by Supran and colleagues³.

^cFungal recombinant enzyme, this work.

rather modest, as these enzymes show a weaker affinity for this activator (Table 1). On the other hand, L-Trp has a submicromolar affinity for MreCA which explains its potent activating effect (see discussion later in the text).

Thus, an entire range of amines and amino acids, of types **1–24**, were tested for their efficacy as MreCA activators (Table 2). These compounds were also investigated earlier³ for their activating properties against hCAs and many enzymes from pathogenic organisms, as reported previously^{26–33}. The following structure–activity relationship (SAR) for the activation of MreCA with compounds **1–24** has been documented considering the data in Table 2:

- The compounds which showed the least effective for activating MreCA were L-His, L-/D-Tyr, L-Asp, and L-/D-Glu, with activation constants ranging between 4.04 and 12.8 μ M. These compounds belong to a rather heterogeneous group of amino

- acids, with both deprotonated (Asp, Glu), neutral (Tyr) and protonated (His) side chains at pH 7.4. On the other hand, it seems that in some cases the enantiomer is relevant for this activity, if one compares the differences in K_A between L and D-His, with the last compound being 6.95 times a better activator compared to its diastereoisomer (Table 2).
- ii. Compounds possessing a medium activating effect were D-His, L-Phe, dopamine and 2-(2-aminoethyl)pyridine (derivative **16**), which showed activation constants in the range of 1.84–2.71 μM (Table 1). Again, small structural changes, as in the pair of compounds **15/16**, leads to drastic changes of activity. The two compounds only differ by a CH_2 group, but **15** is 6.26 times a more effective activator compared to **16**.
 - iii. The effective, submicromolar CAAs against MreCA detected here were D-Phe, L-/D-DOPA, and L-/D-Trp, 4-amino-L-phenylalanine, 2-aminoethyl-piperazine/morpholine, histamine, serotonin, some pyridyl-alkylamines, L-Gln, and L-Asn, with K_{AS} of 0.25–0.93 μM . L-adrenaline, with a K_A of 15 nM, was the most effective among all compounds investigated here for the activation of MreCA (Table 2).
 - iv. The activation profile of this fungal enzyme with amino acids and amines is very different from that of the human isoforms hCA I and II, with only L-Asn and L-Gln showing some selectivity for the activation of the fungal versus the human enzymes.

4. Conclusions

CAAs were shown to be involved in metabolic and signalling pathways in fungi, including pathogenic ones, and this mechanism has been proposed to be exploited for the development of antifungals with different mechanisms of action compared to the clinically used agents, for which extensive drug resistance has been documented^{17,24,34}. Indeed, in an animal model of dandruff provoked by *M. globosa*, a related species to *M. restricta*, it has been shown that β -CA inhibition with sulphonamides has a potent antifungal effect³⁵. However, there are no studies to date on the role of CAAs on the life cycle of fungal pathogens. Considering the fact that amines and amino acids as those investigated here are found in high concentrations in many tissues, our present finding may be relevant for a better understanding of processes connected with infectivity and growth of fungal pathogens. L-adrenaline was observed to be the best MreCA activator. Is it a coincidence that stress, i.e. higher circulating amounts of catecholamines such as L-adrenaline, is associated with a worsening of seborrhoeic dermatitis and dandruff?

Acknowledgements

WAD and CTS thank the Australian Research Council for funding. This work was financed in part by l'Oréal.

Disclosure statement

The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

ORCID

Andrea Angeli  <http://orcid.org/0000-0002-1470-7192>
 Clemente Capasso  <http://orcid.org/0000-0003-3314-2411>
 Claudiu T. Supuran  <http://orcid.org/0000-0003-4262-0323>

References

1. (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81. (b) Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. *Expert Opin Drug Discov* 2019;14:1175–97.
2. (a) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist?. *J Enzyme Inhib Med Chem* 2016;31:345–60. (b) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. *Expert Opin Drug Discov* 2017;12:61–88. (c) Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32.
3. (a) Supuran CT. Carbonic anhydrase activators. *Future Med Chem* 2018;10:561–73. (b) Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activation and the drug design. *Curr Pharm Des* 2008;14:708–15. (c) Akocak S, Supuran CT. Activation of α -, β -, γ -, δ -, ζ - and η - class of carbonic anhydrases with amines and amino acids: a review. *J Enzyme Inhib Med Chem* 2019;34:1652–9.
4. (a) Zoccola D, Innocenti A, Bertucci A, et al. Coral carbonic anhydrases: regulation by ocean acidification. *Mar Drugs* 2016;14:109. (b) Bertucci A, Moya A, Tambutté S, et al. Carbonic anhydrases in anthozoan corals – a review. *Bioorg Med Chem* 2013;21:1437–50. (c) Del Prete S, Vullo D, Zoccola D, et al. Activation profile analysis of CruCA4, an α -carbonic anhydrase involved in skeleton formation of the mediterranean red coral, *Corallium rubrum*. *Molecules* 2017;23:66. (d) Dathan NA, Alterio V, Troiano E, et al. Biochemical characterization of the chloroplastic β -carbonic anhydrase from *Flaveria bidentis* (L.) "Kuntze". *J Enzyme Inhib Med Chem* 2014;29:500–4.
5. (a) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria?. *J Enzyme Inhib Med Chem* 2015;30:325–32. (b) Smith KS, Jakubzick C, Whittam TS, Ferry JG. Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. *Proc Natl Acad Sci USA* 1999;96:15184–9.
6. (a) Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. *Expert Opin Ther Pat* 2018;28:713–21. (b) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. *Expert Opin Ther Pat* 2018;28:709–12. (c) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. *Expert Opin Investig Drugs* 2018;27:963–70. (d) Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). *Expert Opin Ther Pat* 2018;28:729–40.
7. (a) Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. *Expert Opin Ther Targets* 2015;19:551–63. (b) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. *Expert Opin Ther Targets* 2015;19:1689–704. (c) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. *Expert Opin Ther Pat* 2018;28:745–54.
8. (a) Ozensoy Guler O, Capasso C, Supuran CT. A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization. *J Enzyme Inhib Med Chem* 2016;31:

- 689–94. (b) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. *J Inorg Biochem* 2012;111:117–29. (c) Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. *Metabolites* 2017;7:E48.
9. (a) Alterio V, Esposito D, Monti SM, et al. Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor. *J Enzyme Inhib Med Chem* 2018;33:151–7. (b) Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I–XIV with a series of substituted phenols including paracetamol and salicylic acid. *Bioorg Med Chem* 2008;16:7424–8. (c) Nocentini A, Bonardi A, Gratteri P, et al. Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms. *J Enzyme Inhib Med Chem* 2018;33:1453–9. (d) Tars K, Vullo D, Kazaks A, et al. Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases. *J Med Chem* 2013;56:293–300.
10. (a) Del Prete S, Vullo D, Scozzafava A, et al. Cloning, characterization and anion inhibition study of the δ -class carbonic anhydrase (TweCA) from the marine diatom *Thalassiosira weissflogii*. *Bioorg Med Chem* 2014;22:531–7. (b) Vullo D, Del Prete S, Osman SM, et al. Sulfonamide inhibition studies of the δ -carbonic anhydrase from the diatom *Thalassiosira weissflogii*. *Bioorg Med Chem Lett* 2014;24:275–9. (c) Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of the δ -carbonic anhydrase from the marine diatom *Thalassiosira weissflogii*. *J Enzyme Inhib Med Chem* 2014;29:906–11.
11. (a) Supuran CT, Capasso C. An overview of the bacterial carbonic anhydrases. *Metabolites* 2017; 7:56. (b) Clare BW, Supuran CT. Carbonic anhydrase activators. 3: structure–activity correlations for a series of isozyme II activators. *J Pharm Sci* 1994;83:768–73. (c) Supuran CT. Carbonic anhydrases and metabolism. *Metabolites* 2018;8:25. (d) Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? *J Enzyme Inhib Med Chem* 2018;33:485–95.
12. (a) Del Prete S, Vullo D, Fisher GM, et al. Discovery of new family of carbonic anhydrases in the malaria pathogen *Plasmodium falciparum*- the η -carbonic anhydrases. *Bioorg Med Chem* 2014;24:4389–96. (b) De Simone G, Di Fiore A, Capasso C, Supuran CT. The zinc coordination pattern in the η -carbonic anhydrase from *Plasmodium falciparum* is different from all other carbonic anhydrase genetic families. *Bioorg Med Chem Lett* 2015;25:1385–9.
13. Jensen EL, Clement R, Kosta A, et al. A new widespread subclass of carbonic anhydrase in marine phytoplankton. *ISME J* 2019;13:2094–106.
14. (a) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012;112:4421–68. (b) Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. *Eur J Med Chem* 1996;31:1001–10. (c) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. *Nat Rev Drug Discov* 2011;10:767–77. (e) Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. *Curr Med Chem Cardiovasc Hematol Agents* 2004;2:49–68.
15. (a) Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. *J Med Chem* 2011;54:1896–902. (b) Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. *Cancer Res* 2011;71:3364–76. (c) Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. *Chem Commun (Camb)* 2010;46:8371–3. (d) Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. *Angew Chem Int Ed Engl* 2007;46:7697–9.
16. (a) Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. *Angew Chem Int Ed Engl* 2014;53:4231–5. (b) El-Gazzar MG, Nafie NH, Nocentini A, et al. Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates. *J Enzyme Inhib Med Chem* 2005;20:333–40. (c) Eldehna WM, Abo-Ashour MF, Berrino E, et al. SLC-0111 enamionone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX. *Bioorg Chem* 2019;83:549–58. (d) Abo-Ashour MF, Eldehna WM, Nocentini A, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: Determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. *Bioorg Chem* 2019;87:794–802.
17. (a) Akocak S, Lolak N, Nocentini A, et al. Synthesis and biological evaluation of novel aromatic and heterocyclic bis-sulfonamide Schiff bases as carbonic anhydrase I, II, VII and IX inhibitors. *Bioorg Med Chem* 2017;25:3093–7. (b) Akocak S, Lolak N, Bua S, et al. Synthesis and biological evaluation of novel N,N-diaryl cyanoguanidines acting as potent and selective carbonic anhydrase II inhibitors. *Bioorg Chem* 2018;77:245–51. (c) Lolak N, Akocak S, Bua S, et al. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. *Bioorg Chem* 2018; 77:542–7. (d) Akocak S, Lolak N, Bua S, et al. Discovery of novel 1,3-diaryltriazene sulfonamides as carbonic anhydrase I, II, VII, and IX inhibitors. *J Enzyme Inhib Med Chem* 2018; 33:1575–80.
18. (a) Lolak N, Akocak S, Bua S, Supuran CT. Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors. *Bioorg Chem* 2019;82:117–22. (b) Lolak N, Akocak S, Bua S, et al. Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and inhibitors. *Bioorg Med Chem* 2019;27:1588–94. (c) Shabana AM, Mondal UK, Alam R, et al. pH-sensitive multiligand gold nanoplatfrom targeting carbonic anhydrase IX enhances the delivery of Doxorubicin to hypoxic tumor spheroids and overcomes the hypoxia-induced chemoresistance. *ACS Appl Mater Interfaces* 2018; 10:17792–808.
19. (a) Briganti F, Mangani S, Orioli P, et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic

- investigations for the interaction of isozymes I and II with histamine. *Biochemistry* 1997;36:10384–92. (b) Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with L- and D-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. *Chemistry* 2006;12:7057–66. (c) Temperini C, Scozzafava A, Vullo D, Supuran CT. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. *J Med Chem* 2006;49:3019–27. (d) Temperini C, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase activators: kinetic and X-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I–XIV. *Bioorg Med Chem* 2008;16:8373–8. (e) Temperini C, Innocenti A, Scozzafava A, et al. Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. *Bioorg Med Chem Lett* 2007;17:628–35.
20. (a) De Simone G, Di Fiore A, Truppo E, et al. Exploration of the residues modulating the catalytic features of human carbonic anhydrase XIII by a site-specific mutagenesis approach. *J Enzyme Inhib Med Chem* 2019;34:1506–10. (b) Buonanno M, Di Fiore A, Langella E, et al. The crystal structure of a hCA VII variant provides insights into the molecular determinants responsible for its catalytic behavior. *Int J Mol Sci* 2018;19:1571. (c) Mikulski R, West D, Sippel KH, et al. Water networks in fast proton transfer during catalysis by human carbonic anhydrase II. *Biochemistry* 2013;52:125–31.
21. (a) Akocak S, Lolak N, Vullo D, et al. Synthesis and biological evaluation of histamine Schiff bases as carbonic anhydrase I, II, IV, VII, and IX activators. *J Enzyme Inhib Med Chem* 2017;32:1305–12. (b) Akocak S, Lolak N, Bua S, et al. α -Carbonic anhydrases are strongly activated by spinaceamine derivatives. *Bioorg Med Chem* 2019;27:800–4. (c) Akocak S, Lolak N, Bua S, et al. Activation of human α -carbonic anhydrase isoforms I, II, IV and VII with bis-histamine Schiff bases and bis-spinaceamine substituted derivatives. *J Enzyme Inhib Med Chem* 2019;34:1193–8. (d) Dave K, Scozzafava A, Vullo D, et al. Pyridinium derivatives of histamine are potent activators of cytosolic carbonic anhydrase isoforms, I, II and VII. *Org Biomol Chem* 2011;9:2790–800. (e) Dave K, Ilies MA, Scozzafava A, et al. An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II. *Bioorg Med Chem Lett* 2011;21:2764–8.
22. (a) Bhatt A, Mondal UK, Supuran CT, et al. Crystal structure of carbonic anhydrase ii in complex with an activating ligand: implications in neuronal function. *Mol Neurobiol* 2018;55:7431–7. (b) Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. *Bioorg Med Chem Lett* 2006;16:5152–6. (c) Temperini C, Scozzafava A, Puccetti L, Supuran CT. Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators. *Bioorg Med Chem Lett* 2005;15:5136–41. (d) Draghici B, Vullo D, Akocak S, et al. Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect. *Chem Commun* 2014;50:5980–3.
23. (a) Canto de Souza L, Provensi G, Vullo D, et al. Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. *Neuropharmacology* 2017;118:148–56. (b) Sanku RKK, John JS, Salkovitz M, et al. Potential learning and memory disruptors and enhancers in a simple, 1-day operant task in mice. *Behavioural Pharmacol* 2018;29:482–92. (c) Wang X, Schröder HC, Schlossmacher U, et al. Modulation of the initial mineralization process of SaOS-2 cells by carbonic anhydrase activators and polyphosphate. *Calcif Tissue Int* 2014;94:495–509.
24. (a) Del Prete S, Vullo D, Ghobril C, et al. Cloning, purification, and characterization of a β -carbonic anhydrase from *Malassezia restricta*, an opportunistic pathogen involved in dandruff and seborrheic dermatitis. *Int J Mol Sci* 2019;20:2447. (b) Prete SD, Angeli A, Ghobril C, et al. Anion inhibition profile of the β -carbonic anhydrase from the opportunistic pathogenic fungus *Malassezia restricta* involved in dandruff and seborrheic dermatitis. *Metabolites* 2019;9:E147. (c) Del Prete S, Angeli A, Ghobril C, et al. Sulfonamide inhibition profile of the β -carbonic anhydrase from *Malassezia restricta*, an opportunistic pathogen triggering scalp conditions. *Metabolites* 2020;10:39.
25. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. *J Biol Chem* 1971;246:2561–73.
26. (a) Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase activators: Activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. *Bioorg Med Chem Lett* 2007;17:4107–12. (b) Pastorekova S, Vullo D, Nishimori I, et al. Carbonic anhydrase activators: Activation of the human tumor-associated isozymes IX and XII with amino acids and amines. *Bioorg Med Chem* 2008;16:3530–6. (c) Innocenti A, Hilvo M, Parkkila S, et al. Carbonic anhydrase activators: activation of the membrane-associated isoform XV with amino acids and amines. *Bioorg Med Chem Lett* 2009;19:3430–3.
27. (a) Innocenti A, Zimmerman SA, Scozzafava A, et al. Carbonic anhydrase activators: Activation of the archaeal β -class (Cab) and γ -class (Cam) carbonic anhydrases with amino acids and amines. *Bioorg Med Chem Lett* 2008;18:6194–8. (b) Vullo D, Del Prete S, Capasso C, Supuran CT. Carbonic anhydrase activators: activation of the β -carbonic anhydrase from *Malassezia globosa* with amino acids and amines. *Bioorg Med Chem Lett* 2016;26:1381–5. (c) Isik S, Kockar F, Aydin M, et al. Carbonic anhydrase activators: activation of the β -carbonic anhydrase Nce103 from the yeast *Saccharomyces cerevisiae* with amino acids and amines. *Bioorg Med Chem Lett* 2009;19:1662–5.
28. Innocenti A, Leewattanapasuk W, Manole G, et al. Carbonic anhydrase activators: activation of the β -carbonic anhydrase from the pathogenic yeast *Candida glabrata* with amino acids and amines. *Bioorg Med Chem Lett* 2010;20:1701–4.
29. (a) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the α - and β -carbonic anhydrases from the pathogenic bacterium *Vibrio cholerae* with amines and amino acids. *J Enzyme Inhib Med Chem* 2018;33:227–33. (b) Angeli A, Del Prete S, Donald WA, et al. The γ -carbonic anhydrase from the pathogenic bacterium *Vibrio cholerae* is potently activated by amines and amino acids. *Bioorg Chem* 2018;77:1–5. (c) Angeli A, Del Prete S, Osman SM, et al. Activation studies with amines and amino acids of the β -carbonic

- anhydrase encoded by the Rv3273 gene from the pathogenic bacterium *Mycobacterium tuberculosis*. *J Enzyme Inhib Med Chem* 2018;33:364–9.
30. (a) Angeli A, Del Prete S, Pinteala M, et al. The first activation study of the β -carbonic anhydrases from the pathogenic bacteria *Brucella suis* and *Francisella tularensis* with amines and amino acids. *J Enzyme Inhib Med Chem* 2019; 34:1178–85. (b) Stefanucci A, Angeli A, Dimmito MP, et al. Activation of β - and γ -carbonic anhydrases from pathogenic bacteria with tripeptides. *J Enzyme Inhib Med Chem* 2018; 33:945–50. (c) Bua S, Haapanen S, Kuuslahti M, et al. Activation studies of the β -carbonic anhydrase from the pathogenic protozoan *Entamoeba histolytica* with amino acids and amines. *Metabolites* 2019;9:26–33.
31. (a) Vullo D, Del Prete S, Osman SM, et al. Burkholderia pseudomallei γ -carbonic anhydrase is strongly activated by amino acids and amines. *Bioorg Med Chem Lett* 2017;27: 77–80. (b) Vullo D, Del Prete S, Osman SM, et al. Comparison of the amine/amino acid activation profiles of the β - and γ -carbonic anhydrases from the pathogenic bacterium *Burkholderia pseudomallei*. *J Enzyme Inhib Med Chem* 2018;33:25–30.
32. (a) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the γ -carbonic anhydrases from the Antarctic marine bacteria *Pseudoalteromonas haloplanktis* and *Colwellia psychrerythraea* with amino acids and amines. *Marine Drugs* 2019;17: 238–46. (b) Angeli A, Alasmary FAS, Del Prete S, et al. The first study of a δ -carbonic anhydrase: TweCA δ from the diatom *Thalassiosira weissflogii* is effectively activated by amines and amino acids. *J Enzyme Inhib Med Chem* 2018; 33:680–5. (c) Angeli A, Buonanno M, Donald WA, et al. The zinc – but not cadmium – containing ζ -carbonic from the diatom *Thalassiosira weissflogii* is potentially activated by amines and amino acids. *Bioorg Chem* 2018;80:261–5.
33. (a) Angeli A, Del Prete S, Alasmary FAS, et al. The first activation studies of the η -carbonic anhydrase from the malaria parasite *Plasmodium falciparum* with amines and amino acids. *Bioorg Chem* 2018; 80:94–8. (b) Angeli A, Donald WA, Parkkila S, Supuran CT. Activation studies with amines and amino acids of the β -carbonic anhydrase from the pathogenic protozoan *Leishmania donovani chagasi*. *Bioorg Chem* 2018;78:406–10.
34. Capasso C, Supuran CT, Protozoan, fungal and bacterial carbonic anhydrases targeting for obtaining anti-infectives. In: Supuran CT, Capasso, C. ed. Targeting carbonic anhydrases. London: Future Science Ltd.; 2014:133–141. (b) Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO₂-sensing carbonic anhydrase Can2 from the pathogenic fungus *Cryptococcus neoformans*. *J Mol Biol* 2009;385:1207–20.
35. Hewitson KS, Vullo D, Scozzafava A, et al. Molecular cloning, characterization and inhibition studies of a β -carbonic anhydrase from *Malassezia globosa*, a potential antidandruff target. *J Med Chem* 2012;55:3513–20.
36. Nguyen GTH, Tran TN, Podgorski MN, et al. Nanoscale ion emitters in native mass spectrometry for measuring ligand-protein binding affinities. *ACS Cent Sci* 2019;5:308–18.